Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2019-01-30 Interim / Quarterly Rep…
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Appendix 4C - Quarterly 9 pages 860.9KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX/Media Release dated 31 January 2019, titled "Botanix Pharmaceuticals Quarterly Activities Report and 4C Quarterly Cash Flow Report". It contains detailed information about clinical development progress, business development, and corporate cash flow data for the quarter ended 31 December 2018. The presence of the Appendix 4C Quarterly Cash Flow report, which is a regulatory requirement for Australian listed entities to report quarterly cash flows, confirms this is a quarterly report. The document includes substantive financial data such as cash flows from operating, investing, and financing activities, and detailed narrative on business activities during the quarter. It is not merely an announcement of a report but contains the actual report content. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q4 2018
2019-01-30 English
2019 Outlook Presentation 34 pages 2.7MB
Investor Presentation Classification · 95% confidence The document is a detailed investor presentation from January 2019 by Botanix Pharma. It includes extensive information about the company's value proposition, clinical pipeline, market opportunities, product candidates, team biographies, and strategic outlook. The content focuses on clinical trial phases, market potential, and company strategy rather than financial statements or regulatory filings. There is no indication that this is an official annual or quarterly report, audit report, or earnings release. The document is lengthy (15,000 characters) and contains multiple slides and graphics typical of an investor presentation. Therefore, the most appropriate classification is Investor Presentation (IP).
2019-01-30 English
Investigators Meeting Completed for BTX 1204 Phase 2 Study 3 pages 185.3KB
Capital/Financing Update Classification · 90% confidence The document is an ASX/Media Release dated 25 January 2019 announcing the completion of an Investigator's Meeting for a Phase 2 clinical study of BTX 1204 for atopic dermatitis. It provides details about the study protocol, patient enrollment, and the company's development plans. There are no financial statements, regulatory certifications, or detailed financial data present. The content is primarily an update on clinical trial progress and company activities rather than a formal financial report or regulatory filing. This fits best under the category of Capital/Financing Update (CAP) as it relates to clinical study progress and funding status, which is a form of company update on development and financing activities. The document length (7380 characters) and detailed content support this classification rather than a brief announcement or a full financial report.
2019-01-24 English
Ethics Approval for Phase 2 Atopic Dermatitis Study Received 3 pages 184.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX/Media Release dated 18 December 2018 from Botanix Pharmaceuticals announcing the receipt of ethics approval for a Phase 2 clinical study of BTX 1204 for atopic dermatitis. It details the study design, patient recruitment plans, and market potential. The document is a corporate announcement about clinical trial progress and does not contain financial statements, audit information, management changes, or regulatory filings. It is not a report or transcript but a media release about a clinical trial milestone. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to clinical development progress which is often material to company valuation and financing considerations in biotech companies. The document length (6577 characters) and content confirm it is not a brief announcement or a report publication notice. Confidence is high given the clear nature of the announcement and absence of other report types.
2018-12-17 English
Botanix Presents at International Cannabinoid Summit 19 pages 8.7MB
Investor Presentation Classification · 95% confidence The document is an ASX/Media Release dated 14 December 2018 from Botanix Pharmaceuticals Limited. It announces the company's presentation at the International Cannabinoid Derived Pharmaceuticals Summit. The content includes a detailed investor presentation focusing on the company's clinical programs, development strategy, regulatory approach, and product pipeline. The document is lengthy (15,000 characters) and contains substantive information about the company's business, clinical progress, and strategy, but it is not a formal financial report like an Annual Report or Interim Report. It is also not a transcript of a call, nor an announcement of voting results, nor a regulatory filing or certification. The document is a detailed presentation aimed at investors and stakeholders, focusing on financials, strategy, and market position. Therefore, the most appropriate classification is Investor Presentation (IP).
2018-12-13 English
Appendix 3B 11 pages 292.1KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including classes of securities, number of securities issued, terms, issue price, purpose, and compliance with ASX rules. It references specific ASX rules (e.g., Rule 7.1, 7.1A) and includes calculations related to placement capacity under these rules. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding a new issue of securities by Botanix Pharmaceuticals Limited. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital raising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the announcement itself, not a brief notice or a report publication announcement.
2018-12-05 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.